Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Other Non-Current Liabilities: 2013-2024

Historic Other Non-Current Liabilities for Fortress Biotech (FBIO) over the last 12 years, with Dec 2024 value amounting to $1.8 million.

  • Fortress Biotech's Other Non-Current Liabilities fell 7.82% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 7.82%. This contributed to the annual value of $1.8 million for FY2024, which is 7.24% down from last year.
  • Latest data reveals that Fortress Biotech reported Other Non-Current Liabilities of $1.8 million as of FY2024, which was down 7.24% from $1.9 million recorded in FY2023.
  • Fortress Biotech's 5-year Other Non-Current Liabilities high stood at $2.0 million for FY2021, and its period low was $1.8 million during FY2024.
  • Its 3-year average for Other Non-Current Liabilities is $1.8 million, with a median of $1.8 million in 2022.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first climbed by 4.31% in 2021, then fell by 9.15% in 2022.
  • Over the past 5 years, Fortress Biotech's Other Non-Current Liabilities (Yearly) stood at $1.9 million in 2020, then grew by 4.31% to $2.0 million in 2021, then fell by 9.15% to $1.8 million in 2022, then increased by 2.49% to $1.9 million in 2023, then declined by 7.24% to $1.8 million in 2024.